By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

InDex Pharmaceuticals AB 

Scheeles väg 2

Stockholm    SE-171 77  Sweden
Phone: 46-8-50884730 Fax: 46-8-50884739


SEARCH JOBS


Key Statistics


Email: info@indexpharmab.com
Ownership: Private

Web Site: InDex Pharmaceuticals AB
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
InDex Pharmaceuticals AB Announces Results From COLLECT, A Clinical Trial Of Kappaproct® In The Treatment Of Moderate To Severe Ulcerative Colitis 6/27/2014 8:56:54 AM
InDex Pharmaceuticals AB Closes $20 Million Financing Round, Welcomes NeoMed As New Shareholder 2/25/2014 10:09:13 AM
InDex Pharmaceuticals AB Completes Patient Recruitment in P3 Ulcerative Colitis Study With Kappaproct 4/8/2013 11:35:35 AM
InDex Pharmaceuticals AB Granted Japanese Patent for Novel Treatment of Steroid-Resistant Inflammation 10/24/2012 10:17:21 AM
InDex Pharmaceuticals AB Strengthens IP Position for Kappaproct 9/4/2012 11:19:38 AM
InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early 5/18/2009 8:56:11 AM
The Day In Review: Sanofi-Aventis (France) (SASY.PA) Adds To Generics Business 3/27/2006 6:38:54 PM
InDex Signs $35M Agreement With Serono For Inflammation10/19/2005 5:10:10 PM
Serono (SRA) And Swedish Biotech Company InDex Pharmaceuticals AB Sign Worldwide Agreement To Develop And Commercialize Novel Ulcerative Colitis Treatment10/19/2005 5:10:07 PM
//-->